CAJ | 학술논문

目的：观察依达拉奉对中、重型颅脑损伤（TBI）患者脑水肿及预后的影响。方法选取2011年2月-2014年2月住院治疗的124例中、重型 TBI 脑水肿患者，随机分成治疗组63例、对照组61例。对照组给予常规治疗，治疗组在此基础上予依达拉奉静脉滴注。观察治疗前及治疗后第3、7、14、28天的脑水肿面积、治疗第28天的格拉斯哥昏迷量表（GCS）评分及随访6个月后的 Glasgow 预后评分（GOS）。结果2组治疗后第3、7天脑水肿面积均较治疗前显著扩大（P ＜0．01）；第14、28天脑水肿面积显著减小（P ＜0．01）；治疗组显著小于对照组（P ＜0．01）。治疗第28天，2组 GCS 评分均较治疗前显著升高（P ＜0．01）；治疗组显著高于对照组（P ＜0．01）。随访6个月后，治疗组 GOS 评分良好率显著高于对照组（P ＜0．05）。结论依达拉奉可显著减轻中、重型 TBI 患者的脑水肿，改善预后。
목적：관찰의체랍봉대중、중형로뇌손상（TBI）환자뇌수종급예후적영향。방법선취2011년2월-2014년2월주원치료적124례중、중형 TBI 뇌수종환자，수궤분성치료조63례、대조조61례。대조조급여상규치료，치료조재차기출상여의체랍봉정맥적주。관찰치료전급치료후제3、7、14、28천적뇌수종면적、치료제28천적격랍사가혼미량표（GCS）평분급수방6개월후적 Glasgow 예후평분（GOS）。결과2조치료후제3、7천뇌수종면적균교치료전현저확대（P ＜0．01）；제14、28천뇌수종면적현저감소（P ＜0．01）；치료조현저소우대조조（P ＜0．01）。치료제28천，2조 GCS 평분균교치료전현저승고（P ＜0．01）；치료조현저고우대조조（P ＜0．01）。수방6개월후，치료조 GOS 평분량호솔현저고우대조조（P ＜0．05）。결론의체랍봉가현저감경중、중형 TBI 환자적뇌수종，개선예후。
Objective To observe the influence of edaravone on hydrocephalus and prognosis of patients with moderate and severe traumatic brain injury (TBI).Methods 124 patients with hy-drocephalus due to moderate and severe TBI admitted were randomly divided into treatment group (n =63)and control group (n =61).Routine treatment was given to control group,on which basis edara-vone was intravenously injected to treatment group.Hydrocephalus volumes before treatment and 3,7, 14 and 28 days after treatment,Glasgow Coma Scale (GCS)scores 28 days after treatment as well as Glasgow Outcome Scale (GOS)scores 6 months after follow up were observed.Results Hydroceph-alus volumes 3 and 7 days after treatment extended significantly than those before treatment in both groups (P <0.01),decreased apparently 14 and 28 days after treatment (P <0.01),and were smal-ler in treatment group than in control group (P <0.01 ).28 days after treatment,GCS scores in-creased significantly in both groups than those before treatment (P <0.01)and were higher in treat-ment group than in control group (P <0.01).6 months after follow up,GOS score was better in treat-ment group than in control group (P <0.05).Conclusion Edaravone can significantly reduce hydro-cephalus in patients with moderate and severe TBI and improve the prognosis.